相关实验视频

Updated: Sep 10, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

用勃利祖马布治疗的晚期非小细胞肺癌的预测结果

Vamsidhar Velcheti¹, Xuezheng Sun², Maya Hanna³

¹Division of Hematology & Oncology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL, USA.

|August 25, 2025

概括

在接受第一线维持免疫治疗的高级非小细胞肺癌患者中,有限的实验数据显示体重减轻,PD- L1状态和性别影响结果. 持续出现的不良结果表明,

科学领域:

癌症学
免疫疗法
现实世界中的证据

背景情况:

对于高级/转移性非小细胞肺癌 (a/mNSCLC) 的第一线维持治疗,现实数据有限.
了解治疗模式和结果对于优化患者护理至关重要.

研究的目的:

在a/mNSCLC中分析基于pembrolizumab的1LM的实际结果.
确定临床结果的预测因素,包括到下一次治疗或死亡的时间 (rwTTNTD) 和整体存活率 (rwOS).

主要方法:

从2017年6月到2021年9月的电子健康记录的回顾性分析.
包括患有III/ IV期非小细胞癌的患者 (≥18岁),在基化疗后启动了基于pembrolizumab的1LM.
使用多变量分析评估了rwTTNTD,rwOS和相关预测因素.

主要成果:

1944名患者接受了勃利祖马布 (51. 9%) 或勃利祖马布单独治疗 (48. 1%).
中位数为9. 2个月,中位数为18. 7个月.
较短 rwTTNTD 和 rwOS 的显著预测因素包括体重减轻 (5% - < 10% 或 ≥ 10%).
较长的rwTTNTD和rwOS与更高的编程死亡配体1 (PD- L1) 表达 (1% - 49%或≥50%) 和女性性别有关.

结论:

一线治疗,减肥,PD-L1状态和性别是a/mNSCLC现实结果的关键预测因素.
尽管有免疫疗法, 但结果仍然不佳,
需要进一步的研究来改善这种患者群体的治疗策略.

关键词:

电子健康记录其他非小细胞肺癌孟布罗利祖马布佩米特雷克斯后期研究

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...